Dopaminergic Modulation of Decision Making and Subjective Well-Being

Robb B. Rutledge, Nikolina Skandali, Peter Dayan, Raymond J. DolanJournal of Neuroscience 2015 · DOI

Abstract

The neuromodulator dopamine has a well established role in reporting appetitive prediction errors that are widely considered in terms of learning. However, across a wide variety of contexts, both phasic and tonic aspects of dopamine are likely to exert more immediate effects that have been less well characterized. Of particular interest is dopamine's influence on economic risk taking and on subjective well-being, a quantity known to be substantially affected by prediction errors resulting from the outcomes of risky choices. By boosting dopamine levels using levodopa (l-DOPA) as human subjects made economic decisions and repeatedly reported their momentary happiness, we show here an effect on both choices and happiness. Boosting dopamine levels increased the number of risky options chosen in trials involving potential gains but not trials involving potential losses. This effect could be better captured as increased Pavlovian approach in an approach-avoidance decision model than as a change in risk preferences within an established prospect theory model. Boosting dopamine also increased happiness resulting from some rewards. Our findings thus identify specific novel influences of dopamine on decision making and emotion that are distinct from its established role in learning.

Introduction

While dopamine is well-characterized as a signal for "Reward Prediction Errors" (RPEs) in reinforcement learning, its immediate, "tonic" influence on decision-making and emotional states is less understood. Clinical observations have shown that dopaminergic drugs can trigger compulsive gambling in Parkinson’s patients, yet the underlying mechanism remains debated. Does dopamine alter the fundamental calculation of utility (Prospect Theory), or does it act as a "Pavlovian approach" signal, nudging individuals toward potential rewards? Furthermore, the causal role of dopamine in modulating subjective happiness—the emotional response to winning—remains controversial. This study pharmacologically boosts dopamine in healthy subjects to untangle its effects on economic choice and emotional well-being.

Methods

The researchers conducted a within-subject, double-blind, placebo-controlled study with 30 healthy young adults. Participants received either a placebo or 150 mg of levodopa (L-DOPA), a dopamine precursor, before performing a decision-making task.

Experimental Task

The task consisted of 300 trials divided into three categories:

  • Gain trials: Choosing between a certain small gain and a gamble for a larger gain or zero.
  • Loss trials: Choosing between a certain small loss and a gamble for a larger loss or zero.
  • Mixed trials: Choosing between a gamble for a gain/loss and a certain outcome of zero.

Every 3–4 trials, subjects reported their momentary happiness on a visual analog scale.

Sequence of the happiness rating task used to measure subjective well-being throughout the experiment.

Computational Modeling

Two primary models were compared to explain the choice data: a standard Prospect Theory Model and an Approach-Avoidance Model which adds a value-independent "bias" parameter ($\beta$), representing a Pavlovian tendency to approach rewards or avoid threats regardless of the mathematical expected value.

Results

The study revealed that boosting dopamine levels has a highly specific effect on behavior and emotion, rather than causing a general state of recklessness or euphoria.

Valence-Specific Risk-Taking

L-DOPA significantly increased gambling in gain trials ($p = 0.04$) but had no significant effect on loss or mixed trials. This suggests dopamine's influence is dependent on the positive valence of the environment. A significant correlation was also observed between the effective drug dose (mg/kg) and the increase in gain-related gambling ($p < 0.01$).

Comprehensive overview of the experimental task (A), choice behavior (B, C), and the correlation between L-DOPA dosage and increased gambling in gain trials (D).

Pavlovian Approach vs. Risk Preference

Computational modeling showed that the Approach-Avoidance model significantly outperformed the Prospect Theory model (lower BIC). L-DOPA did not change risk aversion ($\alpha$) or loss aversion ($\lambda$) parameters. Instead, it increased the $\beta_{gain}$ parameter, indicating that dopamine acts as a "go" signal for potential prizes rather than changing the mathematical calculation of risk.

The "Small Win" Boost

While L-DOPA did not increase average happiness, it specifically heightened the happiness reported after winning small rewards ($p = 0.03$). On placebo, small wins had minimal impact on mood; on L-DOPA, their emotional impact was significantly amplified. This suggests dopamine modulates the sensitivity of emotional responses to rewards.

Discussion

These findings demonstrate that dopamine influences decision-making through a Pavlovian approach mechanism rather than by altering risk preferences. The valence-specific effect on gain trials provides a potential mechanism for the gambling side effects seen in clinical populations treated with dopaminergic drugs.

Limitations and Future Work

The authors acknowledge potential task confounds where the "risky" option was always the one with the largest potential reward. Future research should investigate if dopamine increases risk-taking per se or simply the approach toward the largest available reward. Additionally, the lack of effect on happiness for large rewards might be due to a ceiling effect on the rating scale. Clinically, the findings suggest that dopaminergic treatments might address anhedonia by specifically restoring the emotional impact of small, everyday rewards.

Summary updated

Abstract

The neuromodulator dopamine has a well established role in reporting appetitive prediction errors that are widely considered in terms of learning. However, across a wide variety of contexts, both phasic and tonic aspects of dopamine are likely to exert more immediate effects that have been less well characterized. Of particular interest is dopamine's influence on economic risk taking and on subjective well-being, a quantity known to be substantially affected by prediction errors resulting from the outcomes of risky choices. By boosting dopamine levels using levodopa (l-DOPA) as human subjects made economic decisions and repeatedly reported their momentary happiness, we show here an effect on both choices and happiness. Boosting dopamine levels increased the number of risky options chosen in trials involving potential gains but not trials involving potential losses. This effect could be better captured as increased Pavlovian approach in an approach-avoidance decision model than as a change in risk preferences within an established prospect theory model. Boosting dopamine also increased happiness resulting from some rewards. Our findings thus identify specific novel influences of dopamine on decision making and emotion that are distinct from its established role in learning.
BibTeX
@article{rutledge2015dopaminergic,
  author = {Robb B. Rutledge and Nikolina Skandali and Peter Dayan and Raymond J. Dolan},
  title = {{Dopaminergic Modulation of Decision Making and Subjective Well-Being}},
  journal = {Journal of Neuroscience},
  year = {2015},
  doi = {10.1523/jneurosci.0702-15.2015},
}
Figure